JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

185.34 -1.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

183.42

Massimo

189.08

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.81% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.7B

10B

Apertura precedente

187.32

Chiusura precedente

185.34

Notizie sul Sentiment di mercato

By Acuity

3%

97%

1 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 feb 2026, 23:57 UTC

Discorsi di Mercato

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Discorsi di Mercato

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Discorsi di Mercato

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Discorsi di Mercato

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Discorsi di Mercato

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Discorsi di Mercato

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Discorsi di Mercato

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Discorsi di Mercato

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Acquisizioni, Fusioni, Takeovers

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisizioni, Fusioni, Takeovers

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Discorsi di Mercato

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Utili

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Utili

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Utili

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Discorsi di Mercato

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Utili

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

19.81% in crescita

Previsioni per 12 mesi

Media 226.7 USD  19.81%

Alto 265 USD

Basso 185 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

9

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

1 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat